Active substance Relatlimab
Domain Oncology and Hematology
Reason of inclusion New medicine (specialité)
Main indication Skin cancer
Extended indication Patients With Previously Untreated Metastatic or Unresectable Melanoma in combination with nivolumab.


Manufacturer BMS
Mechanism of action Immunostimulation
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)
Additional comments Antibody-dependent cell cytotoxicity; T lymphocyte stimulant.


Registration route Centralised (EMA)
Submission date 2021
Expected Registration November 2022
Registration phase Clinical trials
Additional comments De fabrikant verwacht registratie in het vierde kwartaal van 2022.

Therapeutic value

Current treatment options Pembrolizumab, nivolumab, ipilimumab, dabrafenib/trametinib, encorafenib/binimetinib, vemurafenib/cobimetinib.
Therapeutic value No judgement
Duration of treatment Not found
References NCT03470922

Expected patient volume per year

Patient volume

< 80

Market share is generally not included unless otherwise stated.

References NKR
Additional comments Melanoom van de huid betreft 6729 patiënten in 2018, hiervan zijn er 541 patiënten met stadium 3 en 203 patiënten met stadium 4 (maximaal 744 patiënten die in aanmerking komen voor deze behandeling.) Hiervan zijn zo'n 80 patiënten behandeld met nivolumab, dit lijkt de meest waarschijnlijke groep waar dit middel ingezet gaat worden.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Acute myeloid leukaemia; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours.
References Adisinsight.
Additional comments Fase 2 studies

Other information

There is currently no futher information available.